SG11202106244RA - Modified urokinase-type plasminogen activator polypeptides and methods of use - Google Patents
Modified urokinase-type plasminogen activator polypeptides and methods of useInfo
- Publication number
- SG11202106244RA SG11202106244RA SG11202106244RA SG11202106244RA SG11202106244RA SG 11202106244R A SG11202106244R A SG 11202106244RA SG 11202106244R A SG11202106244R A SG 11202106244RA SG 11202106244R A SG11202106244R A SG 11202106244RA SG 11202106244R A SG11202106244R A SG 11202106244RA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- plasminogen activator
- type plasminogen
- modified urokinase
- activator polypeptides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21031—Urokinase (3.4.21.31)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862786302P | 2018-12-28 | 2018-12-28 | |
PCT/US2019/068839 WO2020140101A1 (en) | 2018-12-28 | 2019-12-27 | Modified urokinase-type plasminogen activator polypeptides and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202106244RA true SG11202106244RA (en) | 2021-07-29 |
Family
ID=69400631
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202106244RA SG11202106244RA (en) | 2018-12-28 | 2019-12-27 | Modified urokinase-type plasminogen activator polypeptides and methods of use |
Country Status (15)
Country | Link |
---|---|
US (1) | US20230242895A1 (en) |
EP (1) | EP3902913A1 (en) |
JP (1) | JP2022516725A (en) |
KR (1) | KR20210110848A (en) |
CN (1) | CN113661239A (en) |
AU (1) | AU2019413431A1 (en) |
CA (2) | CA3123872A1 (en) |
CL (1) | CL2021001710A1 (en) |
CO (1) | CO2021008338A2 (en) |
IL (1) | IL284323A (en) |
JO (1) | JOP20210146A1 (en) |
MX (1) | MX2021007843A (en) |
PE (1) | PE20211664A1 (en) |
SG (1) | SG11202106244RA (en) |
WO (1) | WO2020140101A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ760116A (en) | 2017-06-22 | 2024-03-22 | Vertex Pharma | Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use |
CN114854728B (en) * | 2022-05-12 | 2023-11-24 | 云南师范大学 | Proline racemase and preparation and application thereof |
Family Cites Families (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US844A (en) | 1838-07-17 | Boiler for | ||
US5990A (en) | 1848-12-26 | of baltimore | ||
US569A (en) | 1838-01-09 | Caruiag-e-spiiln g | ||
US5795A (en) | 1848-09-19 | Saddletree for carts | ||
US5324A (en) | 1847-10-09 | Cooking-stove | ||
US237A (en) | 1837-06-15 | Egbert beale | ||
US4044126A (en) | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
GB1429184A (en) | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4952496A (en) | 1984-03-30 | 1990-08-28 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US4997766A (en) | 1986-07-11 | 1991-03-05 | American Home Products Corporation | Poly-kringle plasminogen activator |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
EP0266032A1 (en) * | 1986-08-29 | 1988-05-04 | Beecham Group Plc | Modified fibrinolytic enzyme |
US5580559A (en) | 1986-12-05 | 1996-12-03 | Ciba-Geigy Corporation | Hybrid plasminogen activator |
NL8701021A (en) | 1987-04-29 | 1988-11-16 | Stichting Centraal Lab | HUMANE T-PA (U-PA) SUBSTITUTION-MUTANT PROTEINS, CODING RECOMBINANT DNA, TRANSFECTED HOST CELLS, PREPARATION OF THE MUTANT PROTEINS, AND PHARMACEUTICAL PREPARATIONS. |
US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
EP0336508A1 (en) * | 1988-04-06 | 1989-10-11 | K.U. Leuven Research & Development | Recombinant human single-chain urokinase-type plasminogen activator mutant produced by site-specific mutagenesis of lysine 158 to histidine 158 |
AU3410289A (en) | 1988-04-22 | 1989-11-24 | Collaborative Research Inc. | Plasminogen activators with increased fibrin selectivity |
GB8822147D0 (en) | 1988-09-21 | 1988-10-26 | Ciba Geigy Ag | Pharmaceutically active combination |
JPH04506897A (en) | 1988-10-27 | 1992-12-03 | ネーデルランセ オルハニサチエ フォール トゥーヘパスト―ナツールウェーテンシャッペ ルック オンデルズク テーエヌオー | Thrombolytic agents with modified kringle domains |
ATE226636T1 (en) | 1989-03-06 | 2002-11-15 | Univ Texas | SERPIN RESISTANT T-PA; MUTANTS; GENE |
EP0387380A1 (en) * | 1989-03-17 | 1990-09-19 | BEHRINGWERKE Aktiengesellschaft | Mutants of urinary plasminogen activator, their production and use |
JPH04506148A (en) | 1989-04-07 | 1992-10-29 | カンサーフォースクニングスフォンデン・アフ・1989(フォンデン・チル・フレメ・アフ・エクスペリメンテル・カンサーフォースクニング) | Urokinase-type plasminogen activator receptor |
US5891664A (en) | 1989-04-07 | 1999-04-06 | Cancerforskningsfondet Af 1989 | Vectors and methods for recombinant production of uPA-binding fragments of the human urokinase-type plasminogen receptor (uPAR) |
US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
DE3921528A1 (en) | 1989-06-30 | 1991-01-10 | Draegerwerk Ag | MEASURING CELL FOR ELECTROCHEMICAL GAS DETECTION |
US5129569A (en) | 1989-12-21 | 1992-07-14 | Stanton Norman C | Apparatus to attach a flexible covering to a semi-rigid member |
US5648253A (en) | 1990-12-20 | 1997-07-15 | Tsi Corporation | Inhibitor-resistant urokinase |
US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
GB9216558D0 (en) | 1992-08-04 | 1992-09-16 | British Bio Technology | Modified proteases |
US5571708A (en) | 1993-04-19 | 1996-11-05 | Bristol-Myers Squibb Company | Thrombin-activatable plasminogen activator |
AU7097094A (en) | 1993-06-01 | 1994-12-20 | Enzon, Inc. | Carbohydrate-modified polymer conjugates with erythropoietic activity |
US5472692A (en) * | 1993-07-02 | 1995-12-05 | New England Deaconess Hospital Corporation | Pro-urokinase mutants |
US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
CZ288926B6 (en) | 1994-03-31 | 2001-09-12 | Amgen Inc. | MGDF derivative, process of its preparation and pharmaceutical preparation in it is comprised |
US5811252A (en) | 1994-07-07 | 1998-09-22 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Modified proenzymes as substrates for proteolytic enzymes |
US5759542A (en) | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
WO1996013160A1 (en) | 1994-11-01 | 1996-05-09 | New England Deaconess Hospital | Use of urokinase-type plasminogen activators to inhibit hiv infectivity |
US5980886A (en) | 1994-12-14 | 1999-11-09 | University Of Washington | Recombinant vectors for reconstitution of liver |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
US7070925B1 (en) | 1996-07-16 | 2006-07-04 | Gen-Probe Incorporated | Method for determining the presence of an RNA analyte in a sample using a modified oligonucleotide probe |
US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
US6258351B1 (en) | 1996-11-06 | 2001-07-10 | Shearwater Corporation | Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels |
US6448369B1 (en) | 1997-11-06 | 2002-09-10 | Shearwater Corporation | Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
WO1999045026A1 (en) | 1998-03-05 | 1999-09-10 | Chiron Corporation | Method for increasing the serum half-life of a biologically active molecule |
US20020106775A1 (en) | 1999-03-05 | 2002-08-08 | Jieyi Wang | Highly crystalline urokinase |
AU2903899A (en) | 1998-03-12 | 1999-09-27 | Shearwater Polymers Inc. | Poly(ethylene glycol) derivatives with proximal reactive groups |
WO2000002017A2 (en) | 1998-07-03 | 2000-01-13 | Neles Field Controls Oy | Method and arrangement for measuring fluid |
US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
EP1157275A4 (en) | 1999-02-28 | 2003-01-15 | Univ Washington | Novel transduction molecules and methods for using same |
JO2291B1 (en) | 1999-07-02 | 2005-09-12 | اف . هوفمان لاروش ايه جي | Erythopintin derivatives |
US6461802B1 (en) | 1999-08-02 | 2002-10-08 | Agfa-Gevaert | Adhesive layer for polyester film |
WO2001032711A2 (en) | 1999-10-21 | 2001-05-10 | Board Of Trustees Of The University Of Arkansas | Adeno-associated virus aav rep78 major regulatory protein, mutants thereof and uses thereof |
ATE317868T1 (en) | 1999-12-22 | 2006-03-15 | Nektar Therapeutics Al Corp | STERICALLY HINDERED DERIVATIVES OF WATER SOLUBLE POLYMERS |
US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
WO2001062827A2 (en) | 2000-02-22 | 2001-08-30 | Shearwater Corporation | N-maleimidyl polymer derivatives |
AU7485301A (en) | 2000-05-16 | 2001-11-26 | Bolder Biotechnology Inc | Methods for refolding proteins containing free cysteine residues |
US6680178B2 (en) | 2000-06-02 | 2004-01-20 | The Regents Of The University Of California | Profiling of protease specificity using combinatorial fluorogenic substrate libraries |
GB0103110D0 (en) | 2000-08-25 | 2001-03-28 | Aventis Pharma Inc | A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1 |
WO2002040503A2 (en) | 2000-11-17 | 2002-05-23 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the plau gene |
MXPA00011713A (en) | 2000-11-28 | 2002-05-31 | Tgt Lab S A De C V | Re-combining viral and non-viral vectors containing the human gene of the urokinase plasminogen activator and its benefit in the treatment of diverse types of hepatic, renal, pulmonary, pancreatic and cardiac fibrosis and hypertrophic scars. |
DE60144439D1 (en) | 2000-12-20 | 2011-05-26 | Hoffmann La Roche | CONJUGATES OF ERYTHROPOIETIN (EPO) WITH POLYETHYLENE GLYCOL (PEG) |
TWI246524B (en) | 2001-01-19 | 2006-01-01 | Shearwater Corp | Multi-arm block copolymers as drug delivery vehicles |
US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
DE10153601A1 (en) | 2001-11-02 | 2003-05-22 | Paion Gmbh | DSPA for the treatment of stroke |
AU2002352524B2 (en) | 2001-11-07 | 2007-10-04 | Nektar Therapeutics | Branched polymers and their conjugates |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
US7192468B2 (en) | 2002-04-15 | 2007-03-20 | Fluor Technologies Corporation | Configurations and method for improved gas removal |
KR20120088836A (en) | 2002-10-02 | 2012-08-08 | 리전츠 오브 더 유니버시티 오브 캘리포니아 | Methods of generating and screening for proteases with altered specificity |
KR20040040782A (en) | 2002-11-08 | 2004-05-13 | 선바이오(주) | Novel hexa-arm polyethylene glycol and its derivatives and the methods of preparation thereof |
US20040147027A1 (en) | 2003-01-28 | 2004-07-29 | Troy Carol M. | Complex for facilitating delivery of dsRNA into a cell and uses thereof |
US20060178297A1 (en) | 2003-01-28 | 2006-08-10 | Troy Carol M | Systems and methods for silencing expression of a gene in a cell and uses thereof |
DK1596887T3 (en) | 2003-02-26 | 2022-06-20 | Nektar Therapeutics | Polymer-Factor VIII conjugate |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
US7610156B2 (en) | 2003-03-31 | 2009-10-27 | Xencor, Inc. | Methods for rational pegylation of proteins |
CN1311076C (en) | 2003-04-16 | 2007-04-18 | 普罗特奥姆技术公司 | Method for producing recombinaton urokinase |
CA2426115A1 (en) | 2003-04-18 | 2004-10-18 | Victor Gurewich | Methods, devices, and compositions for lysis of occlusive blood clots while sparing wound sealing clots |
KR100512483B1 (en) | 2003-05-07 | 2005-09-05 | 선바이오(주) | Novel Preparation method of PEG-maleimide PEG derivatives |
DK2644206T3 (en) | 2003-05-23 | 2019-06-11 | Nektar Therapeutics | PEG derivatives containing two PEG chains |
US7595306B2 (en) | 2003-06-09 | 2009-09-29 | Alnylam Pharmaceuticals Inc | Method of treating neurodegenerative disease |
AU2004316996A1 (en) | 2003-06-20 | 2005-09-15 | The Regents Of The University Of California | Polypeptide transduction and fusogenic peptides |
PT1718677E (en) | 2003-12-19 | 2012-07-18 | Genentech Inc | Monovalent antibody fragments useful as therapeutics |
GB0405330D0 (en) | 2004-03-10 | 2004-04-21 | Astrazeneca Ab | Enzyme and preparation method |
US7811771B2 (en) | 2004-12-23 | 2010-10-12 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Method for the functional determination of mannan-binding-lectin associated serine proteases (MASPs) and complexes thereof |
EP1940457B1 (en) | 2005-10-21 | 2012-12-12 | Catalyst Biosciences, Inc. | Modified proteases that inhibit complement activation |
JP2009513158A (en) | 2005-11-01 | 2009-04-02 | アリゾナ ボード オブ リージェンツ ア ボディー コーポレート アクティング オン ビハーフ オブ アリゾナ ステイト ユニバーシティ | Novel protein transduction domains and uses thereof |
US7579318B2 (en) | 2005-12-06 | 2009-08-25 | Centre De La Recherche De La Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
KR100859972B1 (en) | 2006-02-20 | 2008-09-25 | 이화여자대학교 산학협력단 | Cell membrane-penetrating peptide |
EP1867661A1 (en) | 2006-06-12 | 2007-12-19 | Diatos | Compositions and methods for delivering anti-activated ras antibodies into cells |
US20090010916A1 (en) | 2006-06-22 | 2009-01-08 | Victor Gurewich | C-1 Inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis |
EP2046951B1 (en) | 2006-07-05 | 2011-10-26 | Catalyst Biosciences, Inc. | Protease screening methods and proteases identified thererby |
EP2242501A4 (en) | 2008-01-09 | 2011-10-19 | Intrexon Corp | Therapeutic inhibitors of pai-1 function methods of their use |
-
2019
- 2019-12-27 EP EP19845802.8A patent/EP3902913A1/en active Pending
- 2019-12-27 KR KR1020217023898A patent/KR20210110848A/en active Search and Examination
- 2019-12-27 MX MX2021007843A patent/MX2021007843A/en unknown
- 2019-12-27 JP JP2021538046A patent/JP2022516725A/en active Pending
- 2019-12-27 PE PE2021001091A patent/PE20211664A1/en unknown
- 2019-12-27 WO PCT/US2019/068839 patent/WO2020140101A1/en active Application Filing
- 2019-12-27 JO JOP/2021/0146A patent/JOP20210146A1/en unknown
- 2019-12-27 CA CA3123872A patent/CA3123872A1/en active Pending
- 2019-12-27 SG SG11202106244RA patent/SG11202106244RA/en unknown
- 2019-12-27 AU AU2019413431A patent/AU2019413431A1/en active Pending
- 2019-12-27 CA CA3176021A patent/CA3176021A1/en active Pending
- 2019-12-27 CN CN201980093212.XA patent/CN113661239A/en active Pending
-
2021
- 2021-06-23 IL IL284323A patent/IL284323A/en unknown
- 2021-06-25 CO CONC2021/0008338A patent/CO2021008338A2/en unknown
- 2021-06-25 CL CL2021001710A patent/CL2021001710A1/en unknown
-
2023
- 2023-02-10 US US18/167,534 patent/US20230242895A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3176021A1 (en) | 2020-07-02 |
WO2020140101A1 (en) | 2020-07-02 |
CN113661239A (en) | 2021-11-16 |
CO2021008338A2 (en) | 2021-10-29 |
US20230242895A1 (en) | 2023-08-03 |
KR20210110848A (en) | 2021-09-09 |
CA3123872A1 (en) | 2020-07-02 |
JOP20210146A1 (en) | 2023-01-30 |
PE20211664A1 (en) | 2021-08-26 |
IL284323A (en) | 2021-08-31 |
JP2022516725A (en) | 2022-03-02 |
AU2019413431A1 (en) | 2021-07-08 |
EP3902913A1 (en) | 2021-11-03 |
MX2021007843A (en) | 2021-08-11 |
CL2021001710A1 (en) | 2021-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202011308VA (en) | Activatable cytokine polypeptides and methods of use thereof | |
SG11202011349PA (en) | Activatable interleukin-2 polypeptides and methods of use thereof | |
IL259514A (en) | Conditionally active heterodimeric polypeptides and methods of use thereof | |
IL288373A (en) | Flt3l-fc fusion proteins and methods of use | |
IL272332A (en) | Antigen-presenting polypeptides and methods of use thereof | |
IL273918A (en) | Trispecific proteins and methods of use | |
EP3902911C0 (en) | Polypeptides useful for gene editing and methods of use | |
IL292871A (en) | Activatable cytokine polypeptides and methods of use thereof | |
SG10201913699QA (en) | Glucagon-receptor selective polypeptides and methods of use thereof | |
IL280102A (en) | Pd1-4-1bbl variant fusion protein and methods of use thereof | |
IL279475A (en) | Ectonucleotidase inhibitors and methods of use thereof | |
IL284323A (en) | Modified urokinase-type plasminogen activator polypeptides and methods of use | |
IL287768A (en) | Kcnt1 inhibitors and methods of use | |
IL287751A (en) | Kcnt1 inhibitors and methods of use | |
IL284640A (en) | Pcsk9 inhibitors and methods of use thereof | |
SG11202010925UA (en) | Masp-2 inhibitors and methods of use | |
IL276687A (en) | Trialkyne linking agents and methods of use | |
IL287973A (en) | Acss2 inhibitors and methods of use thereof | |
IL274504A (en) | Acss2 inhibitors and methods of use thereof | |
IL280103A (en) | Sirpalpha-4-1bbl variant fusion protein and methods of use thereof | |
IL284661A (en) | Pcsk9 inhibitors and methods of use thereof | |
IL277963A (en) | Bicyclic carboxamides and methods of use thereof | |
IL287966A (en) | Auto-injector and related methods of use | |
IL283782A (en) | Anellosomes and methods of use | |
IL249740A0 (en) | Selective dual inhibitors of pi3 delta and gamma protein kinases |